Online Database of Chemicals from Around the World
| Futoh Chemicals Co., Ltd. | Japan | Inquire | ||
|---|---|---|---|---|
 | www.futoh.co.jp | |||
 | +81 (52) 521-8171 | |||
 | +81 (52) 521-8793 | |||
 | tokoro@futoh.co.jp | |||
| Chemical manufacturer | ||||
| chemBlink Standard supplier since 2007 | ||||
| Changshu League Chemical Co., Ltd. | China | Inquire | ||
|---|---|---|---|---|
| www.league-chem.com | |||
| +86 (512) 5254-6388 5254-6399 | |||
| +86 (512) 5254-0118 | |||
| league@league-chem.com | |||
| Chemical manufacturer since 1985 | ||||
| chemBlink Standard supplier since 2007 | ||||
| Manus Aktteva | India | Inquire | ||
|---|---|---|---|---|
| www.manusaktteva.in | |||
| +91 (79) 6512-3395 | |||
| +91 (79) 2646-3395 | |||
| products@manusakttevabiopharma.in | |||
| Chemical distributor | ||||
| chemBlink Standard supplier since 2008 | ||||
| BOC Sciences | USA | Inquire | ||
|---|---|---|---|---|
| www.bocsci.com | |||
| +1 (631) 485-4226 | |||
| +1 (631) 614-7828 | |||
| info@bocsci.com | |||
| Chemical manufacturer | ||||
| chemBlink Standard supplier since 2010 | ||||
| Medilink Pharmachem | India | Inquire | ||
|---|---|---|---|---|
| www.medilinkpharma.com | |||
| +91 (79) 3007-0133 | |||
| +91 (79) 4007-4175 | |||
| exports@medilinkpharma.com | |||
| Chemical distributor since 1996 | ||||
| chemBlink Standard supplier since 2014 | ||||
| Santa Cruz Biotechnology, Inc. | USA | Inquire | ||
|---|---|---|---|---|
| www.scbt.com | |||
| +1 (831) 457-3800 | |||
| +1 (831) 457-3801 | |||
| scbt@scbt.com | |||
| Chemical manufacturer | ||||
| Classification | API >> Nervous system medication >> Cholinergic |
|---|---|
| Name | Neostigmine bromide |
| Synonyms | Prostigmin; (m-Hydroxyphenyl)trimethyl-ammonium bromide dimethylcarbamate |
| Molecular Structure |  |
| Molecular Formula | C12H19BrN2O2 |
| Molecular Weight | 303.20 |
| CAS Registry Number | 114-80-7 |
| EC Number | 204-054-8 |
| Melting point | 172 °C |
|---|---|
| Water solubility | 1 g/ mL |
| Hazard Symbols |  T Details | ||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Risk Statements | R25;R36/37/38;R42/43 Details | ||||||||||||||||||||||||||||||||||||||||||||||||
| Safety Statements | S22;S26;S28A;S37/39;S45 Details | ||||||||||||||||||||||||||||||||||||||||||||||||
| Hazard Classification | |||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||
| SDS | Available | ||||||||||||||||||||||||||||||||||||||||||||||||
| Market Analysis Reports |
| List of Reports Available for Neostigmine bromide |
